Cirius Therapeutics, which is developing therapies for the treatment of liver and metabolic diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The San Diego, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol CSTX. Cirius Therapeutics filed confidentially on October 11, 2018. Citi and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
